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NPAT is an in vivo substrate of cyclin E-Cdk2 kinase and is thought to play a critical role in coordinated
transcriptional activation of histone genes during the G1/S-phase transition and in S-phase entry in mamma-
lian cells. Here we show that NPAT transcription is up-regulated at the G1/S-phase boundary in growth-
stimulated cells and that the NPAT promoter responds to activation by E2F proteins. We demonstrate that
endogenous E2F proteins interact with the promoter of the NPAT gene in vivo and that induced expression of
E2F1 stimulates NPAT mRNA expression, supporting the idea that the expression of NPAT is regulated by E2F.
Consistently, we find that the E2F sites in the NPAT promoter are required for its activation during the
G1/S-phase transition. Moreover, we show that the expression of NPAT accelerates S-phase entry in cells
released from quiescence. The inhibition of NPAT expression by small interfering RNA duplexes impedes cell
cycle progression and histone gene expression in tissue culture cells. Thus, NPAT is an important E2F target
that is required for cell cycle progression in mammalian cells. As NPAT is involved in the regulation of
S-phase-specific histone gene transcription, our findings indicate that NPAT links E2F to the activation of
S-phase-specific histone gene transcription.
Histone proteins facilitate the packing of eukaryotic DNA
into chromatin fibers. Histones are not simply static structural
components of the chromosomes; instead, they participate
actively in the regulation of multiple cellular processes that
involve chromosomal DNA, such as DNA replication, tran-
scription, DNA repair, recombination, and chromosome seg-
regation (22). The bulk biosynthesis of histones is tightly cou-
pled with DNA replication during S phase of the cell cycle. It
is known that both transcriptional regulatin and posttranscrip-
tional regulation are involved in the production of the linker
histone (H1) and the core histones (H2A, H2B, H3, and
H4) in S phase (6, 14, 33, 44). However, the molecular mech-
anism(s) coordinating the expression of the multiple histone
genes remains to be elucidated. Unbalanced or precocious
expression of histones results in the loss of chromosomes and
thus in the loss of yeast viability (25), underscoring the impor-
tance of coordinated histone synthesis in S phase.
We have shown that NPAT is an in vivo substrate of cyclin
E-Cdk2, a cyclin-dependent kinase regulating the G1/S-phase
transition (7, 21, 55). The protein concentration of NPAT is
cell cycle regulated in mammalian cells, and the overexpression
of NPAT promotes S-phase entry in transformed cells (55).
NPAT protein associates with histone gene clusters in vivo,
and the expression of NPAT activates the transcription of
multiple histone genes, suggesting that NPAT plays a crucial
role in the coordinated transcriptional activation of histone
genes at the G1/S-phase transition. Furthermore, the phos-
phorylation of NPAT by cyclin E-Cdk2 regulates its ability to
activate histone gene transcription (24, 56). Therefore, NPAT
provides a link between the cell cycle machinery and the reg-
ulation of histone gene transcription.
The E2F transcription factors are key regulators of cell pro-
liferation, development, differentiation, and apoptosis (8, 13,
18, 27, 28, 38, 45, 51). For regulating cellular proliferation, they
are known to regulate the transcription of a number of genes
involved in the G1/S-phase transition and DNA replication in
mammalian cells. Functional E2F activity consists of an E2F
subunit and a DP subunit. Six E2F proteins (E2F1 to E2F6)
and two DP proteins (DP1 and DP2) are present in mamma-
lian cells. All E2F proteins share a conserved DNA binding
domain and a domain involved in dimerizing with the DP
proteins. E2F1 to E2F5 contain a transactivation domain, and
these E2F proteins activate transcription from promoters bear-
ing E2F binding sites in transient transfection assays. It is
believed, however, that E2F1 to E2F3 are potent transcrip-
tional activators, while E2F4 and E2F5 function as transcrip-
tional repressors by recruiting the pRB family of proteins
(pRB, p107, and p130) to E2F sites in vivo. Unlike the other
E2Fs, E2F6 lacks a transcription activation domain and does
not interact with the pRB family of proteins. E2F6 may func-
tion as a transcriptional repressor, possibly thorough modifying
chromatin structure (8, 13, 27, 31, 48). Genetic studies with
mice deficient in E2F genes have confirmed that E2F proteins
play essential roles in the regulation of the G1/S-phase transi-
tion (11, 15, 53).
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To elucidate the molecular mechanism regulating NPAT
expression and the contribution of NPAT expression to cell
proliferation, we investigated the transcriptional regulation of
NPAT and the effect of the inhibition of NPAT expression on
cell cycle progression. Here we report that NPAT expression is
regulated by the E2F transcription factors. In addition, we
demonstrate that NPAT accelerates S-phase entry in cells re-
leased from growth arrest and that the inhibition of NPAT
expression by small interfering RNA (siRNA) impedes pro-
gression through various phases of the cell cycle in mammalian
cells. Finally, we show that, consistent with the notion that
NPAT plays a critical role in histone gene expression, histone
mRNA levels are greatly reduced when NPAT expression is
inhibited by siRNA.
MATERIALS AND METHODS
Cell culture and cell cycle analysis. Human WI38, U2OS, and mouse NIH 3T3
cells (American Type Culture Collection) were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, unless otherwise
specified. Pools of early-passage WI38-HAER-E2F1 cells were generated by
infection with pBabePuro-HAER-E2F1 (49) and selected in 1.5 g of puromy-
cin/ml. Distributions of cells in the cell cycle were analyzed by fluorescence-
activated cell sorting (FACS) as previously described (55).
Plasmids. The plasmids used for the expression of E2F proteins were previ-
ously described (23). NPAT promoter fragments were amplified by PCR from
previously described cosmid clones containing genomic DNA sequences for the
ATM and NPAT genes (16). Amplified NPAT promoter fragments were cloned
into the pGL3-basic luciferase reporter plasmid (Promega). The nucleotide at
the 5 end of a cDNA clone which contains the most 5 sequence of NPAT from
among the isolated NPAT cDNA clones is designated position 1. pGL-N2750
contains nucleotides 2750 to 22 (which is 44 nucleotides upstream from the
initiation codon of the NPAT gene). pGL-N536, pGL-N134, pGL-N86, and
pGL-N30 contain nucleotides 536, 134, 86, and 30 to 22 of the NPAT
upstream sequence, respectively.
Northern blot analysis. NIH 3T3 cells were starved in 0.1% serum for 48 h and
then stimulated with 20% serum for various times. Total RNA was isolated by
using a Qiagen RNeasy kit as described by the manufacturer. Thirty to 40 g of
isolated RNA was separated on a 1.2% formaldehyde-agarose gel and trans-
ferred to a Hybond N membrane (Amersham). A hybridization probe was
prepared from a mouse NPAT expressed sequence tag clone (AI642904). Hy-
bridization was carried out by using Ambion Ultrasensitive Hybridization Buffer
as described by the manufacturer.
We infected WI38 cells with a retrovirus (pBabe-ERE2F1) that expresses
human E2F1 fused with the ligand binding domain of the estrogen receptor
(ER-E2F1) to generate ER-E2F1-expressing cells. For analysis of NPAT mRNA
in ER-E2F-expressing cells, ER-E2F-expressing WI38 clones were plated on the
day before induction. The ER-E2F1 fusion protein was activated by adding
4-hydroxytamoxifen (OHT) to a final concentration of 300 nM, and samples were
harvested 4 h after induction. Cycloheximide was added when needed at a final
concentration of 10 g/ml. Total RNA was isolated by the CsCl ultracentrifu-
gation method (1). Poly(A) RNA was subsequently isolated by using an Amer-
sham poly(A) RNA purification kit as described by the manufacturer. Four to
8 g of poly(A) RNA was separated on a 1.25% formaldehyde–agarose gel,
transferred to a Hybond N membrane, and probed as described previously (1).
For analysis of histone mRNAs from siRNA-treated cells (see below), the cells
were cotransfected with a plasmid expressing a puromycin resistance gene
(pBabePuro). At 24 h after transfection, puromycin (1.5 g/ml) was added to the
culture medium to select for puromycin-resistant (transfected) cells. At 48 h after
the addition of puromycin, the cells were harvested, and total RNA was isolated
by using an RNeasy kit as described above. Thirty micrograms of isolated RNA
was used for analysis as described above. The hybridization probes for histone
mRNAs were prepared from PCR-amplified DNA by using clone BAC, which
contains histone genes from the human chromosome 6 cluster (56), as the
template. The hybridization signals were quantitated by using a phosphorimager
(Bio-Rad).
Luciferase reporter assays. Cells (U2OS or NIH 3T3) were grown in six-well
plates and transfected with a luciferase reporter construct and various expression
plasmids. For normalization of transfection efficiency, the cells were also co-
transfected with a -galactosidase-expressing plasmid (pCMV-lacZ). Transfec-
tions were carried out by using FuGene6 (Roche) according to the manufactur-
er’s protocol. At various times, the cells were lysed with Promega reporter lysis
buffer, and the luciferase and -galactosidase activities of the lysates were mea-
sured as suggested by Promega.
Chromatin immunoprecipitation assays. Chromatin immunoprecipitation as-
says were performed and analyzed essentially as described by Frank et al. (10).
Briefly, asynchronously growing U2OS cells were cross-linked with 1% formal-
dehyde for 10 min, the reaction was stopped by the addition of glycine, and the
cells were washed in Tris-buffered saline and harvested in sodium dodecyl sulfate
buffer. Following centrifugation, the cells were resuspended in immunoprecipi-
tation buffer and sonicated to yield fragments with an average length of 500 to
1,000 bp. The lysate was precleared and then immunoprecipitated at 4°C over-
night with polyclonal antibodies specific for E2F1 (sc-193; Santa Cruz) or E2F4
(sc-866) or with an unrelated anti-Flag antibody (F3165; Sigma). To recover
immune complexes, blocked protein A beads were added and incubated for 2 h
at 4°C, the beads were washed thoroughly, the complexes were eluted, cross-links
were reversed, and material was recovered by phenol-chloroform extraction and
ethanol precipitation.
DNA was resuspended in 200 l of water, and 7.5 l was used for each
quantitative PCR with 200 nM primers in 25 l of SYBR Green reaction mix
(Perkin-Elmer). Primers were designed with Primer Express 1.0 software (Ap-
plied Biosystems, Foster City, Calif.) under the manufacturer’s suggested con-
ditions. The primer pairs used were as follows: for NPAT, CAGGAGCTGTCG
CTGTGTTTG and TTGTTACCCTCGGACGTAGCC; for p107, AGGCAGA
CGGTGGATGACAACAC and TCAGCGTGGGGCTTGTCCTCGAA; and
for -actin, AACTCTCCCTCCTCCTCTTCCTC and GAGCCATAAAAGGC
AACTTTCGG. The p107 and -actin primers were previously described by
Takahashi et al. (47).
PCRs were performed by using an ABI Prism 7700 sequence detection system.
For each PCR run with SYBR Green I detection, a melting curve analysis was
performed to guarantee the specificity in each reaction tube (absence of primer
dimers and other nonspecific products). Quantitation was performed and ex-
pressed as previously described (10).
Microinjection. Rat1 cells were plated on coverslips and made quiescent by
serum starvation for 48 h. The nuclei of the cells then were microinjected directly
with 50 ng of expression plasmid/l together with 2 g of rabbit immunoglobulin
G (Jackson Laboratories)/l by using a Zeiss automatic injection system. Bro-
modeoxyuridine (BrdU) (100 M) was added immediately after injection; the
cells were fixed 12, 14, and16 h after injection; and the proportion of BrdU-
positive microinjected cells was determined.
Immunofluorescence staining. NPAT protein and BrdU were stained as pre-
viously described (56), except that images were captured by using a SPOT RT
camera (Diagnostic Instrument Inc.) connected to a Zeiss Axiophot Photomi-
croscope.
RNA interference. RNA interference was carried out by using two different
methods. In the first method, synthetic siRNA duplexes were used as described
by Elbashir et al. (9). A synthetic siRNA duplex (NP/KD1) corresponding to the
NPAT mRNA sequence 5-AAGGUUUGCUGGCAGUCAGAG-3 was used
to inhibit NPAT protein expression. A synthetic siRNA duplex (Luc/KD) cor-
responding to the firefly luciferase mRNA sequence 5-AACUUACACGCUG
AGUACUUCGA-3 was used as a negative control. The siRNA duplexes were
purchased from Dharmacon Research, Inc. (Lafayette, Colo.). U2OS cells were
grown on coverslips in six-well plates and transfected with the siRNAs by using
Lipofectamine 2000 (Invitrogen) essentially as described by Elbashir et al. (9).
To monitor transfected cells, a green fluorescent protein (GFP)-expressing plas-
mid (pEGFP; 50 ng) was also cotransfected. BrdU (final concentration, 20 M)
was added to the culture medium 1 h before the cells were fixed. Immunofluo-
rescence staining of NPAT protein and BrdU was performed as previously
described (56).
In the second method, a DNA vector-based approach (46) was used. A double-
stranded oligonucleotide corresponding to the human NPAT mRNA sequence
5-GGGAGATTCTCACCCTGAGTCC 3 was cloned into pBS/U6 (kindly pro-
vided by Yang Shi) to generate pBS/U6/NPAT. One microgram of pBS/U6 or
pBS/U6/NPAT was transfected into U2OS cells by using FuGene6. To monitor
transfected cells, 50 ng of pEGFP was also cotransfected. At 24 h after trans-
fection, the cells were trypsinized and plated on coverslips. Treatment with BrdU
and immunofluorescence staining were carried out as described above.
FACS analysis. U2OS cells were transfected with either pBS/U6 or pBS/
U6/NPAT as described above. For selection of transfected cells, 100 ng of
pCMVCD20 expressing human CD20 was cotransfected. At various times, the
cells were harvested and analyzed for cell cycle distribution by FACS as de-
scribed previously (55).
To calculate the percentage of cells that had moved out of G1 or S phase at 48
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to 53 h posttransfection, the following formulae were used: for calculating the
percentage of cells that had moved out of G1 phase (percent exited G1), percent
exited G1  (percent G1 cells at 48 h  percent G1 cells at 53 h)/percent G1 cells
at 48 h; for calculating the percentage of cells that had moved out of S phase
(percent exited S), percent exited S  [(percent G1 cells at 48 h  percent G1
cells at 53 h  percent S cells at 48 h)  percent S cells at 53 h]/percent G1 cells
at 48 h  percent G1 cells at 53 h  percent S cells at 48 h).
RESULTS
NPAT expression is transcriptionally up-regulated at the
G1/S-phase boundary in cells stimulated to enter the cell cycle
from quiescence. Zhao et al. previously showed that the NPAT
protein concentration is low in early G1 phase and reaches the
maximum level at the G1/S-phase boundary (55). We have also
observed that the NPAT protein concentration diminishes in
serum-starved WI38 cells and increases as cells reenter the cell
cycle (56) (data not shown). These results indicate that NPAT
expression is regulated during cell cycle progression. To deter-
mine whether the expression of NPAT is regulated at the
transcriptional level, we monitored the expression of NPAT
mRNA in NIH 3T3 cells after release from serum starvation.
Figure1A shows that, as expected, serum starvation arrested
NIH 3T3 cells at G0 phase, and the addition of serum to the
medium stimulated the cells to reenter the cell cycle synchro-
nously. The stimulated cells started to enter S phase at about
12 h after serum stimulation, and most cells reached S phase by
16 h after stimulation. NPAT mRNA levels were low in serum-
starved and early-G1-phase NIH 3T3 cells. NPAT mRNA
reached the maximum level at the G1/S-phase boundary (Fig.
1B). NPAT mRNA peaked at about the same time as cyclin E1
mRNA, which is known to be up-regulated during the G1/S-
phase transition (2, 12, 32). Similarly, we have also observed
the up-regulation of NPAT mRNA at the G1/S-phase boundary
in human IMR90 cells released from serum starvation (data
not shown). Consistent with our data, a recent cDNA microar-
ray analysis of gene expression during the cell division cycle of
human HeLa cells showed that NPAT transcription is up-
regulated at the G1/S-phase boundary (52). Together, these
results show that NPAT expression is regulated at the mRNA
level during growth stimulation as well as during the cell divi-
sion cycle.
FIG. 1. NPAT is transcriptionally up-regulated in NIH 3T3 cells following growth stimulation. (A) Cell cycle distribution profiles for NIH 3T3
cells during quiescence and serum stimulation. NIH 3T3 cells were serum starved and restimulated to enter the cell cycle as described in Materials
and Methods. At the indicated times after serum addition, the cell cycle distribution of the cells was analyzed by FACS. (B) Analysis of NPAT
mRNA expression in NIH 3T3 cells treated as described for panel A. NPAT mRNA was analyzed by Northern blotting as described in Materials
and Methods. The analysis of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA in the same samples as a control is also shown.
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Activation of the NPAT promoter by E2F. The human NPAT
gene is localized on chromosome 11q22-q23. The 5 end of the
human NPAT gene is about 0.5 kb away from that of the ATM
gene, and the two genes share a bidirectional promoter (3, 17).
There are two putative E2F recognition sites in close proximity
to the NPAT gene. The NPAT promoter also contains potential
SP1 binding sites next to the putative E2F sites, and the pro-
moter is TATA less (17) (Fig. 2A), a feature reminiscent of
FIG. 2. Activation of the NPAT promoter by E2F. (A) Sequence of the human NPAT promoter. The DNA sequence between the human ATM
and NPAT genes is shown. The two putative E2F recognition sequences are boxed. Two potential SP1 sites are underlined. The 1 position for
NPAT is indicated by the solid arrow. The broken arrow indicates the start site for the ATM gene (41). (B) Activation of the NPAT promoter by
E2F1. A schematic representation of the NPAT promote-luciferase (LUC) reporter constructs is shown on the left. The nucleotide positions of
the NPAT promoter fragments are indicated in parentheses. Site I and site II indicate the two E2F sites. U2OS cells were transfected with 1 g
of pCMV (vector) or 1 g of pCMV-E2F1 together with 50 ng of the indicated NPAT promoter-luciferase reporter construct. For normalization
of transfection efficiency among the different samples, 50 ng of pCMV-lacZ was also cotransfected. At 24 h after transfection, the cells were lysed
and the activities of luciferase and -galactosidase were assayed as described in Materials and Methods. Fold induction was calculated by
comparing the normalized luciferase activity from E2F1-transfected cells with that from vector-transfected cells. The means and standard
deviations from at least three independent experiments are shown. (C) Regulation of the NPAT promoter by E2F proteins. U2OS cells were
transfected with 1 g of pCMV (Vector) or 1 g of the indicated E2F-expressing plasmid together with 50 ng of pGL-N134 and 50 ng of pCMV-lacZ.
The samples were analyzed as described for panel B. The normalized luciferase activity from the cells transfected with the vector was set as 1.
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many known E2F-responsive genes (20). These observations,
together with the finding that NPAT expression is regulated at
the transcriptional level during growth stimulation and cell
cycle progression, prompted us to examine whether the NPAT
promoter is regulated by E2F. We cloned various DNA frag-
ments from the 5 end of the NPAT gene into a luciferase
reporter plasmid and tested their activation by E2F1 in tran-
sient transfection assays (Fig. 2B). Several NPAT promoter
constructs were strongly activated by E2F1. Deletion of nucle-
otides 5 to the putative E2F binding sites in the NPAT pro-
moter did not impede the activation of the NPAT promoter by
E2F1. In contrast, a deletion that removes one putative E2F
binding site (pGL-N86) significantly impaired the activation of
the promoter by E2F1, and deletion of both putative E2F
binding sites (pGL-N30) abolished the activation of the pro-
moter by E2F1 (Fig. 2B). These results suggest that NPAT
transcription is regulated by E2F, presumably through the E2F
recognition sites in the promoter.
To test whether the NPAT promoter can be regulated by
other E2F proteins in addition to E2F1, we cotransfected the
NPAT promoter-luciferase reporter (pGL-N134) with plas-
mids that express E2F1, E2F2, E2F3, or E2F4. As shown in
Fig. 2C, the overexpression of E2F2, E2F3, and E2F4 can also
activate the NPAT promoter. Thus, the NPAT promoter may
respond to regulation by multiple E2F proteins.
The E2F recognition sites are required for the activation of
the NPAT promoter by E2F proteins. The results presented in
Fig. 2B suggest that the putative E2F binding sites in the NPAT
promoter mediate activation by E2F. To test directly the con-
tribution of each of the two E2F sites to the activation of the
NPAT promoter by the E2F proteins, we generated point mu-
tations in these two E2F sites, either individually or in combi-
nation (Fig. 3A), and tested the activation of the mutant NPAT
promoter by the overexpression of the E2F1, E2F2, E2F3, and
E2F4 proteins. As shown in Fig. 3B, mutation of either one of
the E2F sites partially decreases the activation of the NPAT
promoter by E2F1, E2F2, and E2F3. Simultaneous mutation of
both E2F sites almost completely abolishes the activation of
the NPAT promoter by these E2F proteins, indicating that
both E2F sites contribute to the regulation of the NPAT pro-
moter by these three E2F proteins. Unlike the activation by
E2F1, E2F2, and E2F3 overexpression, the activation of the
NPAT promoter by E2F4 overexpression is abolished by mu-
tation at site I, while mutation at site II had no effect on the
activation of the NPAT promoter by E2F4 overexpression;
these results suggest that E2F4 regulates NPAT expression
through one E2F site (site I). In conclusion, these results show
that E2F regulates the NPAT promoter directly through the
E2F recognition sites in the promoter.
Endogenous E2F proteins bind to the NPAT promoter in
vivo, and the induction of E2F1 activates the expression of
endogenous NPAT mRNA. Having shown that the NPAT pro-
moter can be activated by multiple E2F proteins in transient
transfection assays, we sought to determine whether endoge-
nous NPAT mRNA expression is regulated by E2F. We first
examined whether endogenous E2F proteins bind to the NPAT
promoter in vivo. For this purpose, we carried out chromatin
immunoprecipitation assays by using antibodies specific for
E2F1 and E2F4. To ensure that the E2F1 and E2F4 antibodies
that we used can specifically immunoprecipitate the DNA frag-
ments known to be bound by E2F1 and E2F4 in vivo (47), we
tested the immunoprecipitation of p107 promoter sequences
by the E2F1 and E2F4 antibodies. Both E2F antibodies pre-
cipitated promoter fragments from the p107 gene in U2OS
cells (Fig. 4), but these two antibodies precipitated negligible
amounts of promoter fragments from the actin gene, which is
not regulated by E2F. These results demonstrate that the E2F1
and E2F4 antibodies that we used can detect specific interac-
tions of the E2F1 and E2F4 proteins with the promoters reg-
ulated by these two proteins. Similar to the results obtained
with the p107 promoter, the E2F1 and E2F4 antibodies also
immunoprecipitated a DNA fragment from the NPAT pro-
moter, while the control antibody failed to precipitate the same
NPAT promoter fragment (Fig. 4). These results show that
endogenous E2F proteins, at least E2F1 and E2F4, interact
with the NPAT promoter in vivo, supporting the idea that
NPAT expression is regulated by E2F in vivo.
To examine directly whether the expression of E2F activates
endogenous NPAT mRNA expression, we infected WI38 cells
with a retrovirus (pBabe-ERE2F1) that expresses ER-E2F1
and selected clones that express ER-E2F proteins. Vigo et al.
previously showed that ER-E2F fusion proteins are localized
in the cytoplasm and are inactive in the absence of OHT. Upon
FIG. 3. E2F recognition sites are required for activation of the
NPAT promoter by E2F proteins. (A) Nucleotide sequences of E2F
recognition sites in wild-type (WT) and mutant (Mut) NPAT promot-
ers. The mutated nucleotides are shown in bold type. (B) Responses of
wild-type and mutant NPAT promoters to activation by different E2F
proteins. U2OS cells were transfected with the vector or the indicated
E2F-expressing plasmid together with the indicated luciferase reporter
constructs. The samples were analyzed as described in the legend to
Fig. 2B.
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stimulation by OHT, these proteins enter the nucleus and are
activated (49). In addition, the expression of many previously
characterized E2F target genes was demonstrated to be acti-
vated by these ER-E2F proteins (27, 49). As previously re-
ported (26, 49), we found that the ER-E2F1 protein was lo-
calized in the cytoplasm in the absence of OHT and entered
the nucleus rapidly when cells were treated with OHT (data
not shown). The activation of ER-E2F1 significantly increased
NPAT mRNA expression, even in the presence of the protein
synthesis inhibitor cycloheximide (Fig. 5A). We also observed
the induction of NPAT mRNA expression by activated ER-
E2F2 and ER-E2F3 proteins (data not shown). These results
suggest that NPAT transcription is regulated by E2F in vivo.
Consistent with previous reports (5, 17), while a single band
was detected for NPAT mRNA in mouse cells (Fig. 1B), two
NPAT mRNA bands were observed in human cells (Fig. 5A).
The origin of the two NAPT mRNA-specific bands detected in
human cells remains to be determined. In addition to up-
regulation at the mRNA level, the NPAT protein was also
up-regulated upon activation of ER-E2F1 (Fig. 5B), most
likely as a result of the increased NPAT mRNA level. Thus, the
activation of E2F1 not only can induce the transcription of
NPAT but also results in an increase in the NPAT protein
concentration.
The E2F sites mediate NPAT promoter activation at the
G1/S-phase transition. Given that NPAT mRNA levels reach a
maximum at the G1/S-phase boundary after cells are stimu-
lated to enter the cell cycle (Fig. 1) and that the overexpression
of E2F activates the transcription of NPAT (Fig. 2 and 5A), it
is possible that E2F regulates the expression of NPAT via the
E2F sites in its promoter during growth stimulation. To test
this possibility, we examined the activities of the wild-type and
E2F site-mutated NPAT promoters in serum-starved cells as
well as in cells stimulated to reenter the cell cycle. The NPAT
promoter activity was low in serum-starved (G0) and early-G1-
phase cells, and the promoter activity was markedly up-regu-
lated when cells reached late G1/early S phase (Fig. 6). This
observation is consistent with our analysis of endogenous
NPAT mRNA expression in NIH 3T3 cells during serum stim-
ulation (Fig. 1). Mutation of the 3 E2F site (site II) reduced
FIG. 4. E2F proteins bind the NPAT promoter in vivo. Chromatin immunoprecipitation analysis was performed with U2OS cell extracts by
using the indicated antibodies. Immunoprecipitated promoter fragments were analyzed by quantitative PCR to determine the relative presence of
E2F1 and E2F4 on the indicated promoters as described in Materials and Methods. All results are representative of at least two independent
immunoprecipitations and are reported as means and standard deviations.
FIG. 5. Activation of E2F1 results in increased expression of NPAT. (A) E2F1 up-regulates NPAT mRNA expression. ER-E2F1-expressing
WI38 cells were treated with OHT and cycloheximide (CHX) or not treated for 4 h as indicated. mRNA was isolated and analyzed by Northern
blotting. As previously reported (17), two NPAT mRNA bands were detected in human cells. As a positive control, the cyclin E1 (CCNE1) mRNA
in the same samples was also analyzed. EtBr, ethidium bromide staining of the 28S RNA, used as a loading control. (B) Western blot analysis of
NPAT protein in ER-E2F1-expressing cells following OHT treatment. The NPAT protein was detected by using a mouse monoclonal anti-NPAT
antibody (56). The analysis of the actin protein, serving as a loading control, is also shown.
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the activation of the promoter, while mutation of the 5 E2F
site (site I) completely abolished the activation of the promoter
by serum stimulation. These results show that both E2F bind-
ing sites in the NPAT promoter contribute to the activation
of the NPAT promoter at the G1/S-phase boundary during
growth stimulation and that the 5 E2F site (site I) appears
to play a more important role than the 3 E2F site (site II)
in the up-regulation of NPAT expression during growth
stimulation.
The expression of NPAT accelerates S-phase entry in se-
rum-stimulated cells. E2F1, E2F2, and E2F3 are potent tran-
scriptional activators of E2F-responsive genes, such as Cdc6,
cyclin E1, and Cdc25A, that are required for S-phase entry (8,
13, 27, 48). The overexpression of any of these E2F proteins is
sufficient to induce quiescent cells to enter S phase (19, 23, 37).
In addition, the overexpression of some of the E2F target
genes has been shown to promote S-phase entry in cells re-
leased from quiescence (39, 42, 49). As the overexpression of
NPAT promotes S-phase entry in asynchronously growing
U2OS cells (55), it is possible that the expression of NPAT will
accelerate S-phase entry in cells released from growth arrest.
To test this possibility directly, we microinjected an NPAT-
expressing plasmid into serum-starved Rat1 cells, released the
cells from arrest by adding serum, and monitored the progres-
sion of the injected cells into S phase by measuring BrdU
incorporation. As a positive control for this experiment, we
also microinjected an E2F1-expressing plasmid. As shown in
Fig. 7, cells injected with an NPAT-expressing plasmid incor-
FIG. 6. Activation of the NPAT promoter at the G1/S-phase boundary during growth stimulation depends on E2F recognition sites. NIH 3T3
cells were grown in six-well plates and transfected with 300 ng of wild-type (WT) or mutant (Mut) NPAT promoter constructs as indicated. For
normalization of transfection efficiency, 200 ng of pCMV-lacZ was also cotransfected. At 18 h after transfection, the cells were washed and cultured
in 0.1% serum. Cell proliferation was induced with 20% serum 48 h after serum starvation. At the indicated times, the cells were harvested and
assayed for cell cycle distribution (top) and luciferase and -galactosidase activities. The results shown are the means for triplicate samples. Similar
results were also obtained in another independent experiment (data not shown).
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porated BrdU at a higher rate than cells injected with the
control vector at 12, 14, and 16 h after serum addition. Hence,
the expression of NPAT accelerates the G1/S-phase transition
in cells reentering the cell division cycle. The kinetics of S-
phase entry in NPAT-injected cells are slower than those in
E2F1-injected cells, consistent with reports that E2F regulates
a variety of genes whose functions are critical for S-phase entry
(8, 13, 45, 48).
NPAT function is required for cell cycle progression. Our
studies have shown that NPAT is maximally expressed at the
G1/S-phase boundary and that the overexpression of NPAT
accelerates S-phase entry in asynchronously growing cells as
well as in cells entering the cell cycle from quiescence (55)
(Fig. 1 and 7). These results, together with the observation that
mouse embryos deficient for NPAT fail to develop beyond the
eight-cell stage (5), are consistent with the idea that NPAT
plays a critical role in cell cycle progression. However, it re-
mains to be determined whether NPAT function is essential
for cell cycle progression in somatic cells. Recently, it was
shown that siRNA consisting of duplexes of 21 to 23 nucleo-
tides can induce highly efficient and gene-specific inhibition of
the expression of a specific protein in mammalian cells (4, 9,
35, 36). To address whether NPAT is required for cell cycle
progression, we used RNA interference assays with siRNA
duplexes to inhibit the expression of NPAT protein in cultured
human cells and examined the effect of the inhibition of NPAT
expression on DNA synthesis in asynchronously growing
U2OS cells.
It was previously shown that NPAT protein concentrates at
a few easily detectable nuclear spots that are associated with
histone gene clusters. There are generally five to eight such
NPAT spots in interphase U2OS cells (56). Therefore, we used
immunofluorescence staining to assess the effect of siRNA on
NPAT expression. Transfection of an siRNA targeting human
NPAT mRNA (NP/KD1) but not a control siRNA targeting
firefly luciferase mRNA (Luc/KD) into U2OS cells caused a
dramatic decrease in NPAT protein levels, as judged by the
disappearance of the NPAT spots (Fig. 8A, top panels). siRNA
was highly efficient in eliminating NPAT protein, as the NPAT
staining (spots) disappeared in most of the transfected cells
(Fig. 8B, top panel).
To provide additional evidence that the decrease in NPAT
protein levels caused by siRNA results from specific RNA
interference rather than from nonspecific effects of the chem-
ically synthesized RNA duplexes, we carried out RNA inter-
ference assays with a DNA vector-based approach in which an
siRNA duplex is expressed from a DNA vector in vivo (46). We
constructed a plasmid (pBS/U6/NPAT) that carries the se-
quence for an siRNA duplex targeting a human NPAT se-
quence different from that targeted by the above-discussed
synthetic siRNA. Similar to the transfection of the synthetic
siRNA, the transfection of this plasmid (pBS/U6/NPAT) effi-
ciently inhibited the expression of NPAT protein in U2OS
cells, while the control vector (pBS/U6) had no effect on NPAT
protein expression (Fig. 8A and B, lower panels). Thus, NPAT
expression was specifically inhibited by siRNAs targeting
NPAT sequences.
To examine the effect of the inhibition of NPAT expression
on cell cycle progression, we monitored the incorporation of
BrdU in U2OS cells transfected with either synthetic siRNA
duplexes or plasmid pBS/U6/NPAT. As shown in Fig. 8C and
D, both chemically synthesized siRNA and pBS/U6/NPAT that
specifically targeted NPAT sequences resulted in dramatic de-
creases in BrdU incorporation in transfected cells, while the
control siRNA and control vector pBS/U6 had no effect on
BrdU incorporation. These results demonstrate that NPAT
function is essential for cell cycle progression.
The inhibition of DNA synthesis by the NPAT-specific
siRNAs could result from a block of S-phase entry or from an
inhibition of progression through other phases of the cell cycle.
In order to distinguish between these possibilities, we exam-
ined the cell cycle distribution of cells treated with NPAT-
specific siRNA by FACS analysis. The siRNA-treated cells
were distributed over all phases of the cell cycle, with an
accumulation in G2/M phase (Fig. 9A). These results, together
with the observation that BrdU incorporation was inhibited in
siRNA-treated cells (Fig. 8C and D), suggest that NPAT func-
tion is required for transition through multiple phases of the
cell cycle, including G2/M-phase progression. To test directly
whether progression through the G1 and S phases was inhib-
ited by NPAT-specific siRNA, we compared the rates of G1-
and S-phase progression in siRNA-treated cells with those in
control cells. pBS/U6/NPAT- or control vector pBS/U6-trans-
fected cells were treated with nocodazole to block the reentry
of the cells into G1 phase (55). Subsequently, the fractions of
cells passing through G1 and S phases during a certain period
of time were measured. As shown in Table1 and Fig. 9B,
progression through both G1 and S phases was considerably
slower in siRNA-treated cells than in control cells. Thus, it
appears that NPAT plays a role in cell cycle progression at
multiple control points.
Histone gene expression is inhibited in cells treated with
NPAT-specific siRNA. It has been shown that NPAT associates
with the promoters of replication-dependent histone genes in
vivo and that the overexpression of NPAT activates the histone
promoters (24, 56). We have also observed that induced ex-
pression of NPAT activates the transcription of multiple en-
FIG. 7. NPAT accelerates S-phase entry in Rat1 cells released
from quiescence. Serum-starved, quiescent Rat1 cells were injected
with plasmid pCMV expressing E2F1 or NPAT as indicated. Cells
injected with empty vector pCMV were used as a negative control.
Serum was added, and at 12, 14, and 16 h DNA synthesis was assessed
by measuring BrdU incorporation. Shown here are representative re-
sults from three independent experiments in which more than 200 cells
were microinjected.
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FIG. 8. NPAT is required for cell cycle progression. (A) Inhibition of NPAT expression by siRNAs targeting NPAT. U2OS cells were
transfected with the indicated synthetic siRNA (Luc/KD or NP/KD) or plasmid (pBS/U6 or pBS/U6/NPAT), together with a GFP-expressing
plasmid to label the transfected cells (green). At 60 h (for Luc/KD and NP/KD) or 72 h (for pBSU6 or pBS/U6/NPAT) after transfection, the cells
were fixed and stained with an anti-NPAT antibody (red) to assess the presence or absence of NPAT spots. The nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI) (blue). (B) Analysis of the inhibition of NPAT expression by siRNAs. U2OS cells were transfected and
stained as described for panel A. GFP-positive (transfected) cells were examined for the presence or absence of NPAT spots. Cells with more than
two detectable NPAT spots were scored as NPAT spot-positive cells. Shown are the means and standard deviations from three independent
experiments. More than 200 GFP-positive cells were analyzed in each experiment. (C) Inhibition of BrdU incorporation by siRNAs targeting
NPAT. U2OS cells were transfected as described for panel A. BrdU was added to the culture medium and incubated for 1 h. Cells were then fixed
and stained with an anti-BrdU antibody (red). The nuclei were stained with DAPI. (D) Analysis of the effects of siRNAs on BrdU incorporation.
U2OS cells were treated as described for panel C, and GFP-positive cells were analyzed for BrdU staining. The data represent the means and
standard deviations from three independent experiments. More than 200 GFP-positive cells were analyzed in each experiment.
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dogenous histone genes (data not shown). These results indi-
cate that NPAT regulates histone gene expression. If NPAT is
required for histone gene transcription, then one would predict
that the inhibition of NPAT expression should result in a
reduction in the levels of histone mRNAs in vivo. To examine
this idea, we inhibited NPAT expression by using siRNA and
examined the levels of histone mRNAs in the treated cells by
Northern blot analysis. While glyceraldehyde-3-phosphate de-
hydrogenase mRNA was not affected by NPAT-specific siRNA,
the expression of the mRNAs of all five subtypes of histones was
greatly reduced in siRNA-treated cells (Fig. 10). These results,
together with the results from the above-mentioned previous
studies, strongly support the notion that NPAT plays an essen-
tial role in the expression of replication-dependent histone
genes.
DISCUSSION
NPAT is an in vivo substrate of cyclin E-Cdk2 kinase and
regulates coordinated transcriptional activation of the replica-
tion-dependent histone genes (24, 55, 56). Here we show that
the expression of NPAT is regulated by the E2F transcription
factor. Thus, NPAT links both cyclin E-Cdk2 and E2F to the
regulation of histone gene expression. The fact that the expres-
sion of NPAT function is regulated at both transcriptional and
posttranslational levels by key cell cycle regulators underscores
the notion that NPAT plays a pivotal role in cell cycle progres-
sion. Indeed, our studies demonstrated that the expression of
NPAT promotes S-phase entry in cells released from quies-
cence as well as in cycling cells. In addition, we show that
NPAT function is required for progression through multiple
phases of the cell cycle.
FIG. 9. Effects of inhibition of NPAT expression on cell cycle progression. (A) U2OS cells were transfected with control vector pBS/U6 or
pBS/U6/NPAT. At the indicated time posttransfection, cells were harvested and the cell cycle distributions of the transfected cells were analyzed
by FACS as described in Materials and Methods. The data represent the results from four independent experiments. (B) Inhibition of NPAT
expression attenuates G1- and S-phase progression. The percentages of transfected cells that had moved out of G1 or S phase at 48 to 53 h
posttransfection were calculated from the data presented in Table 1 as described in Materials and Methods.
2830 GAO ET AL. MOL. CELL. BIOL.
 o
n
 July 23, 2018 by PRO
FESSO
R O
F RESEARCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
Several lines of evidence presented in this study indicate that
NPAT is a bona fide E2F target gene. First, in transient trans-
fection experiments, the NPAT promoter is activated by E2F
proteins through the E2F recognition sequences in the pro-
moter. Second, mutations of the E2F sites impair transcrip-
tional activation of the NPAT promoter at the G1/S-phase
boundary during growth stimulation. Third, endogenous E2F
proteins associate with the NPAT promoter in vivo, and the
activation of E2F induces the expression of the endogenous
NPAT gene. Thus, the increased expression of NPAT at the
G1/S-phase boundary likely results, at least partly, from tran-
scriptional regulation by E2F.
E2F proteins interact with proteins in the pRB family that
can elicit transcriptional repression. Thus, E2F proteins can
mediate transcriptional repression as well as transcriptional
activation. It has been proposed that E2F1, E2F2, and E2F3
act as potent transcriptional activators, whereas E2F4 and
E2F5 mediate transcriptional repression (8, 13, 45, 48). Some
studies have suggested that a major role of E2F in cell cycle
progression is to mediate transcriptional repression of the E2F
target genes (40, 54), while genetic studies with cells deficient
in E2F1 to E2F3 have indicated that these E2F proteins are
required for the transcriptional activation of a number of E2F
target genes whose functions are essential for cell cycle pro-
gression (53). Thus, it appears that E2F-mediated transcrip-
tional activation and repression are both crucial for cell cycle
progression. When overexpressed, all four E2F proteins tested
in our experiments can activate the NPAT promoter. However,
it remains to be determined whether the activities of these E2F
proteins are required for NPAT expression in vivo. Given that
endogenous E2F1 and E2F4 proteins are associated with the
NPAT promoter in vivo (Fig. 4), it is likely that at least these
two E2F proteins participate in the regulation of NPAT ex-
pression. E2F1 may positively regulate the NPAT promoter,
whereas E2F4 may function as a repressor of the promoter in
G1 phase. The observed activation of the NPAT promoter by
E2F4 overexpression may result from sequestration of the pRB
family of proteins.
Mutation of the E2F sites in the NPAT promoter either
attenuates or abolishes the activation of the NPAT promoter at
the G1/S-phase boundary during growth stimulation (Fig. 6),
suggesting that E2F regulates transcriptional activation of the
NPAT gene during the G1/S-phase transition. The E2F site(s)
may also mediate transcriptional repression of the endogenous
NPAT promoter, although we did not detect such repression in
our current assays (Fig. 6).
The inhibition of NPAT expression affected cell cycle pro-
gression at multiple stages (Fig. 8 and 9 and Table 1), suggest-
ing a role for NPAT in more than one cellular process. The
observation that the inhibition of NPAT expression attenuates
S-phase entry indicates that NPAT regulates a rate-limiting
step in the G1/S-phase transition. This idea is consistent with
our finding that the overexpression of NPAT promotes G1/S-
phase progression (55) (Fig. 7). It remains to be determined,
however, whether histone synthesis is the rate-limiting step in
NPAT-mediated S-phase entry. In addition to activating his-
tone expression, NPAT may also perform other functions that
are essential for S-phase entry. Our data also indicate that the
rate of S-phase progression is reduced when NPAT expression
is inhibited. Given the observation that NPAT plays a critical
role in histone gene expression (24, 56) (Fig. 10) and the recent
report that the inhibition of histone expression by HIRA over-
expression causes cell cycle arrest in S phase (29), the observed
inhibition of S-phase progression by NPAT-specific siRNA
may result from reduced histone expression. Our present study
has revealed that, in addition to being critical for G1/S-phase
progression, NPAT function is also involved in G2/M-phase
progression (Fig. 9A). Further studies are needed to elucidate
the underlying molecular mechanism. Recent studies have
shown that E2F function is also required throughout the cell
cycle (13, 45, 53). It is possible that some of the E2F functions
are executed through the activities of NPAT.
FIG. 10. Inhibition of histone expression in cells treated with
NPAT-specific siRNA. U2OS cells were transfected with control vec-
tor pBS/U6 or pBS/U6/NPAT and treated as described in Materials
and Methods. Total RNA isolated from transfected cells was analyzed
by Northern blotting. The relative levels of histone mRNAs in pBS/
U6/NPAT-transfected cells compared with those in pBS/U6-trans-
fected cells are shown on the right. GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase.
TABLE 1. Effect of inhibition of NPAT expression
on G1- and S-phase progression
a
Phase
% of cells at the following h after transfection
with the indicated plasmid:
48 55 61 72
U6 U6/NPAT U6 U6/NPAT U6 U6/NPAT U6 U6/NPAT
G1 35.4 22.9 13.4 15.7 10.7 10.1 4.4 5.8
S 43.3 30.1 52.1 35.0 10.9 24.3 3.6 10.8
G2/M 21.3 46.9 34.5 49.4 78.4 65.7 92.0 83.5
a U2OS cells were transfected with pBS/(U6) or pBS/U6/NPAT (U6/NPAT)
as described in Materials and Methods. Nocodazole (50 ng/ml) was added to the
culture medium 48 h after transfection. Cells were harvested at the indicated
times posttransfection, and the distribution of the transfected cells in the cell
cycle was analyzed by FACS. The mean results from two independent experi-
ments are shown.
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During S phase, cells synthesize large quantities of histone
proteins to complex with newly replicated DNA. This is ac-
complished by both transcriptional activation of histone genes
in S phase and posttranscriptional regulation of histone tran-
scripts (6, 14, 33, 44). Although E2F regulates the expression of
a number of genes whose products are involved in DNA rep-
lication, the promoters of most histone genes do not contain
E2F sites and appear not to be directly regulated by E2F (34).
As NPAT regulates histone gene transcription, the observa-
tions in this study suggest that E2F indirectly regulates the
expression of histone genes through its regulation of NPAT
expression. Interestingly, the histone stem-loop binding pro-
tein, which is involved in histone pre-mRNA processing (50),
has also been identified as an E2F target in DNA microarray
analyses of genes induced by E2F (18, 27). Thus, E2F pro-
motes S-phase entry not only by regulating the expression of
proteins involved in DNA synthesis but also by regulating the
expression of proteins involved in histone synthesis.
E2F activity is negatively regulated by tumor suppressor
pRB and related proteins p107 and p130, which in turn are
inactivated by cyclin D-dependent kinase Cdk4/Cdk6. The ac-
tivity of Cdk4/Cdk6 itself is regulated by the INK4 cyclin-
dependent kinase inhibitor family of proteins. This pRB/E2F
pathway is deregulated in virtually all human cancers (30, 43).
In view of our observation that NPAT is a critical target of E2F
and can promote S-phase entry in mammalian cells under
various conditions, it is tempting to speculate that the dereg-
ulated expression of NPAT may also contribute to tumorigen-
esis in human cancers. Further studies are needed to deter-
mine whether the regulation of NPAT may be altered in
human cancers.
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